Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists

Med Res Rev. 2016 Sep;36(5):871-923. doi: 10.1002/med.21395. Epub 2016 May 16.

Abstract

It has now been demonstrated that the μ, δ1 , δ2 , and κ1 opioid receptor (OR) agonists represent the most promising group of opioids for the creation of drugs enhancing cardiac tolerance to the detrimental effects of ischemia/reperfusion (I/R). Opioids are able to prevent necrosis and apoptosis of cardiomyocytes during I/R and improve cardiac contractility in the reperfusion period. The OR agonists exert an infarct-reducing effect with prophylactic administration and prevent reperfusion-induced cardiomyocyte death when ischemic injury of heart has already occurred; that is, opioids can mimic preconditioning and postconditioning phenomena. Furthermore, opioids are also effective in preventing ischemia-induced arrhythmias.

Keywords: cardioprotection; heart; ischemia/reperfusion injury; opioids; signal transduction.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / chemistry
  • Analgesics, Opioid / pharmacology*
  • Animals
  • Anti-Arrhythmia Agents / chemistry
  • Anti-Arrhythmia Agents / pharmacology*
  • Cardiotonic Agents / chemistry
  • Cardiotonic Agents / pharmacology*
  • Drug Discovery
  • Humans
  • Receptors, Opioid / agonists*

Substances

  • Analgesics, Opioid
  • Anti-Arrhythmia Agents
  • Cardiotonic Agents
  • Receptors, Opioid